Rimegepant demonstrated efficacy for acute migraine treatment specifically in triptan-unsuitable adults, filling the treatment gap for this underserved patient population.
Key findingRimegepant demonstrated efficacy for acute migraine treatment specifically in triptan-unsuitable adu
What the researchers found
Rimegepant demonstrated efficacy for acute migraine treatment specifically in triptan-unsuitable adults, filling the treatment gap for this underserved patient population.
Why it matters
Relevant to peptide therapeutics.
How the study worked
In publication.
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial.
Cephalalgia : an international journal of headache, 45(11), 3331024251395298
Citation
Ashina, Messoud; McAllister, Peter; Gaul, Charly; Leyva-Rendon, Adolfo; Ramirez, Luz M; Nalpas, Catherine; Thiry, Alexandra; Abraham, Lucy; Fountaine, Robert J; Fullerton, Terence. (2025). Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial.. Cephalalgia : an international journal of headache, 45(11), 3331024251395298. https://doi.org/10.1177/03331024251395298